Calidi Biotherapeutics CLDI
NYSE CLDI
$0.64 0.00 (-0.75%)
As of: Oct 23, 2026 · 2:46 PM EDT

Calidi Biotherapeutics (CLDI) Receivables - Net (2022 - 2023)

Updated

Calidi Biotherapeutics' Receivables - Net came in at $870.00 for Q2 2023.

Analysis

Calidi Biotherapeutics (CLDI) Receivables - Net (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,127.89 Bn 1,096.47 Bn 19.71 Bn
2 Johnson & Johnson 635.11 Bn 554.97 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.80 Bn 12.70 Bn
4 Merck 358.24 Bn 312.62 Bn 12.21 Bn
5 Novartis Ag 290.13 Bn 254.12 Bn 11.24 Bn
6 Astrazeneca 265.05 Bn 238.74 Bn 12.86 Bn
7 Amgen 237.87 Bn 193.27 Bn 7.24 Bn
8 Gilead Sciences 194.91 Bn 169.11 Bn 6.22 Bn
9 Pfizer 171.28 Bn 117.93 Bn 10.94 Bn
10 Calidi Biotherapeutics 913,319.97 -24.47 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 870.00
Dec 31, 2022 870.00
API Access

Calidi Biotherapeutics Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=CLDI&period=max&api_key=YOUR_API_KEY